TBPH

YUPELRI® (revefenacin)

Chronic obstructive pulmonary disease (COPD)

Quarterly Sales (Approved)

Exp Date

February 26, 2021 (Est)

Amp Volatility Score

N/A

Catalyst Info & Data Links

TITLE: YUPELRI® (revefenacin) for COPD -  Quarterly Sales (Approved)


WHAT IS THE CATALYST EVENT?

  • Quarterly Sales (Approved)


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • February 26, 2021 (Est)


PRIOR DATA/EVENTS

PRESS RELEASE


List last quarter's sales e.g. $13M Q3/2020

2020 Revenue guidance: The Company is changing financial guidance and expects full-year 2020 operating loss, excluding share-based compensation, of $225 million to $235 million.


MECHANISM OF ACTION

  • Revefenacin is a long-acting muscarinic antagonist, which is often referred to as an anticholinergic. It has similar affinity to the subtypes of muscarinic receptors M1 to M5. In the airways, it exhibits pharmacological effects through inhibition of M3 receptor at the smooth muscle leading to bronchodilation. The competitive and reversible nature of antagonism was shown with human and animal origin receptors and isolated organ preparations. In preclinical in vitro as well as in vivo models, prevention of methacholine- and acetylcholine-induced bronchoconstrictive effects was dose-dependent and lasted longer than 24 hours. The clinical relevance of these findings is unknown. The bronchodilation following inhalation of revefenacin is predominantly a site-specific effect.

Updated by HC

TBPH, Chronic obstructive pulmonary disease (COPD), chronic inflammatory lung disease, YUPELRI® (revefenacin)

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon